title: Interpretation of results of the cost-effectiveness analysis reported by Pellissier et al. on October 2007.
authors.forename: M
authors.initials: M
authors.lastname: Najafzadeh
authors.forename: M
authors.initials: M
authors.lastname: Sadatsafavi
authors.forename: C A
authors.initials: CA
authors.lastname: Marra
mesh_terms: D003362:Cost-Benefit Analysis; D006562:Herpes Zoster / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000191:economics*; D006801:Humans; D032541:Mass Vaccination / Q000191:economics; D008875:Middle Aged
chemical_list: D053061:Herpes Zoster Vaccine